Tango Therapeutics Reports Transformative 92% ORR in Pancreatic Cancer Trial, Plans Phase 3
TNGX has more than doubled off its 52-week low of $3.12.
Summary
Tango Therapeutics reported highly positive Phase 1/2 clinical data for its vopimetostat and daraxonrasib combination, showing a 92% objective response rate in pancreatic cancer, leading to plans for Phase 3 development.
Key Events · Product Development and Regulatory · TNGX
-
Exceptional Efficacy in Pancreatic Cancer
The vopimetostat plus daraxonrasib combination achieved a 92% objective response rate (ORR) in response-evaluable PDAC patients, a significant result for this difficult-to-treat cancer.
-
Strong Durability and Safety Profile
The combination demonstrated a 90% 6-month progression-free survival rate and a 100% disease control rate in PDAC, with a generally well-tolerated safety profile and no new safety signals.
-
Advancing to Phase 3 Development
Based on these compelling results, Tango Therapeutics intends to rapidly advance the vopimetostat plus daraxonrasib combination into Phase 3 development for first-line MTAP-deleted pancreatic cancer.
-
Additional Positive Data
The combination also showed a 100% ORR in NSCLC patients and a 52% ORR with vopimetostat plus zoldonrasib in PDAC, further validating the therapeutic approach.
Analysis · TNGX · Life Sciences
Tango Therapeutics announced exceptionally strong initial Phase 1/2 data for its vopimetostat and daraxonrasib combination therapy, achieving a 92% objective response rate (ORR) in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma (PDAC). This represents a potentially transformative breakthrough in a cancer with extremely high unmet medical need, where current treatments offer limited efficacy. The company's plan to rapidly advance this combination into Phase 3 development for first-line pancreatic cancer underscores the significance of these results. The data also showed encouraging durability with a 90% 6-month progression-free survival rate and a favorable safety profile. This news has already driven the stock price above its 52-week high, reflecting strong investor optimism.
At the time of this filing, TNGX was trading at $32.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $3.12 to $28.41. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.